Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2016

01-12-2016 | Original Article

Fluorouracil induces autophagy-related gastric carcinoma cell death through Beclin-1 upregulation by miR-30 suppression

Authors: Chun Yang, Yong Pan

Published in: Tumor Biology | Issue 12/2016

Login to get access

Abstract

The molecular mechanisms underlying the anti-cancer effects of chemotherapy drugs are not completely understood. Here, we studied the effects of fluorouracil (5-FU) on gastric carcinoma (GC) cells. We found that 5-FU dose-dependently inhibited the growth of GC cells, in either a cell counting kit-8 (CCK-8) assay or a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Moreover, autophagy-associated protein 6 (ATG6) or Beclin-1 was dose-dependently activated by 5-FU in GC cells. Further, microRNA (miR)-30 was found to be regulated by 5-FU, and bioinformatics analysis showed that miR-30 targeted the 3′-UTR of Beclin-1 to inhibit its translation. Together, these data suggest that 5-FU may suppress miR-30 to upregulate Beclin-1 to induce autophagic cell death and cell proliferation arrest in GC cells.
Literature
1.
Wu W, Ding H, Cao J, Zhang W. Fbxl5 inhibits metastasis of gastric cancer through suppressing snail1. Cell Physiol Biochem. 2015;35:1764–72.CrossRefPubMed
2.
Attoub S, Karam SM, Nemmar A, Arafat K, John A, Al-Dhaheri W, et al. Short-term effects of oral administration of pistacia lentiscus oil on tissue-specific toxicity and drug metabolizing enzymes in mice. Cell Physiol Biochem. 2014;33:1400–10.CrossRefPubMed
3.
Xu XY, Zhang LJ, Yu YQ, Zhang XT, Huang WJ, Nie XC, et al. Down-regulated mac30 expression inhibits proliferation and mobility of human gastric cancer cells. Cell Physiol Biochem. 2014;33:1359–68.CrossRefPubMed
4.
Wang Y, Gao S, Liu G, Jia R, Fan D, Feng X. Microarray expression profile analysis of long non-coding rnas in human gastric cardiac adenocarcinoma. Cell Physiol Biochem. 2014;33:1225–38.CrossRefPubMed
5.
Zhou X, Xia Y, Su J, Zhang G. Down-regulation of mir-141 induced by helicobacter pylori promotes the invasion of gastric cancer by targeting stat4. Cell Physiol Biochem. 2014;33:1003–12.CrossRefPubMed
6.
Sankpal UT, Lee CM, Connelly SF, Kayaleh O, Eslin D, Sutphin R, et al. Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-clinical evaluation. Cell Physiol Biochem. 2013;32:675–86.CrossRefPubMed
7.
Cui Y, Chen J, He Z, Xiao Y. Suz12 depletion suppresses the proliferation of gastric cancer cells. Cell Physiol Biochem. 2013;31:778–84.CrossRefPubMed
8.
Zhao X, Li X, Yuan H. Micrornas in gastric cancer invasion and metastasis. Front Biosci. 2013;18:803–10.CrossRef
9.
Liu G, Jiang C, Li D, Wang R, Wang W. Mirna-34a inhibits egfr-signaling-dependent mmp7 activation in gastric cancer. Tumour Biol. 2014;35:9801–6.CrossRefPubMed
10.
Mao D, Zhang Y, Lu H, Zhang H. Molecular basis underlying inhibition of metastasis of gastric cancer by anti-vegfa treatment. Tumour Biol. 2014;35:8217–23.CrossRefPubMed
11.
Ye Y, Zhou X, Li X, Tang Y, Sun Y, Fang J. Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of mmp7 and mmp13. Tumour Biol. 2014;35:10891–6.CrossRefPubMed
12.
Zhao Z, Han F, Yang S, Wu J, Zhan W. Oxamate-mediated inhibition of lactate dehydrogenase induces protective autophagy in gastric cancer cells: involvement of the akt-mtor signaling pathway. Cancer Lett. 2015;358:17–26.CrossRefPubMed
13.
Ge J, Chen Z, Huang J, Chen J, Yuan W, Deng Z, et al. Upregulation of autophagy-related gene-5 (atg-5) is associated with chemoresistance in human gastric cancer. PLoS One. 2014;9, e110293.CrossRefPubMedPubMedCentral
14.
Hosogi S, Kusuzaki K, Inui T, Wang X, Marunaka Y. Cytosolic chloride ion is a key factor in lysosomal acidification and function of autophagy in human gastric cancer cell. J Cell Mol Med. 2014;18:1124–33.CrossRefPubMedPubMedCentral
15.
Liu M, Li CM, Chen ZF, Ji R, Guo QH, Li Q, et al. Celecoxib regulates apoptosis and autophagy via the pi3k/akt signaling pathway in sgc-7901 gastric cancer cells. Int J Mol Med. 2014;33:1451–8.PubMedPubMedCentral
16.
Tang C, Yang L, Jiang X, Xu C, Wang M, Wang Q, et al. Antibiotic drug tigecycline inhibited cell proliferation and induced autophagy in gastric cancer cells. Biochem Biophys Res Commun. 2014;446:105–12.CrossRefPubMed
17.
18.
19.
20.
21.
Zhang J, Hummersone M, Matthews CS, Stevens MF, Bradshaw TD. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death. Oncology. 2015;88:28–48.CrossRefPubMed
22.
23.
Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of mirna cancer therapeutics. Drug Discov Today. 2013;18:282–9.CrossRefPubMed
24.
Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through mir-200 family micrornas in vitro and in vivo. Cancer Sci. 2014;105:755–62.CrossRefPubMedPubMedCentral
25.
Wang F, Xiao W, Sun J, Han D, Zhu Y. Mirna-181c inhibits egfr-signaling-dependent mmp9 activation via suppressing akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.CrossRefPubMed
26.
Ouzounova M, Vuong T, Ancey PB, Ferrand M, Durand G, Le-Calvez Kelm F, et al. Microrna mir-30 family regulates non-attachment growth of breast cancer cells. BMC Genomics. 2013;14:139.CrossRefPubMedPubMedCentral
27.
Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, et al. Mir-30 as a tumor suppressor connects egf/src signal to erg and emt. Oncogene. 2014;33:2495–503.CrossRefPubMed
28.
Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010;29:4194–204.CrossRefPubMed
29.
Martinez I, Cazalla D, Almstead LL, Steitz JA, DiMaio D. Mir-29 and mir-30 regulate b-myb expression during cellular senescence. Proc Natl Acad Sci U S A. 2011;108:522–7.CrossRefPubMed
30.
31.
Gewirtz DA. Autophagy and senescence in cancer therapy. J Cell Physiol. 2014;229:6–9.PubMed
Metadata
Title
Fluorouracil induces autophagy-related gastric carcinoma cell death through Beclin-1 upregulation by miR-30 suppression
Authors
Chun Yang
Yong Pan
Publication date
01-12-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3775-6

Other articles of this Issue 12/2016

Tumor Biology 12/2016 Go to the issue

Original article

RETRACTED ARTICLE: Analysis of serum levels and tissue expression of galectin-1 and galectin-3 as noninvasive biomarkers in osteosarcoma patients

Original Article

MMP inhibitor Ilomastat induced amoeboid-like motility via activation of the Rho signaling pathway in glioblastoma cells

Original Article

The long non-coding RNA maternally expressed gene 3 activates p53 and is downregulated in esophageal squamous cell cancer

Original Article

RETRACTED ARTICLE: Regulation of activating protein-4-associated metastases of non-small cell lung cancer cells by miR-144

Original Article

MiRNA-221-3p desensitizes pancreatic cancer cells to 5-fluorouracil by targeting RB1

Original article

RETRACTED ARTICLE: Profiles of tissue microRNAs; miR-148b and miR-25 serve as potential prognostic biomarkers for hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits